Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer

Immune checkpoint inhibitors (ICPis) have revolutionized cancer therapy with broad activities against a wide range of malignancies. However, in many malignancies their efficacy remains limited due to the primary resistance. Furthermore, a high percentage of patients develop progression due to the se...

Descripción completa

Detalles Bibliográficos
Autores principales: Seto, Tiffany, Sam, Danny, Pan, Minggui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410194/
https://www.ncbi.nlm.nih.gov/pubmed/30678257
http://dx.doi.org/10.3390/medsci7020014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410194/
https://www.ncbi.nlm.nih.gov/pubmed/30678257
http://dx.doi.org/10.3390/medsci7020014

Ejemplares similares